Monthly Archives: November 2025


Ultra-Processed Foods: A Key Driver of Modern Health Problems

A growing body of evidence shows that ultra-processed foods are displacing traditional, whole-food diets worldwide and driving major diet-related chronic diseases. Drawing on decades of dietary surveys, global sales data, cohort studies, randomized trials, and mechanistic research, this first paper in a three-part Lancet Series reports that ultra-processed foods have […]


The Surprising Gap in Heart Attack Prediction

Traditional atherosclerotic cardiovascular disease (ASCVD) risk- and symptom-based screening misses nearly half of patients under age 66 who go on to experience their first myocardial infarction (MI), revealing major shortcomings in current preventive strategies. In this US retrospective study of 465 adults presenting with a first type 1 MI, simulation […]


Carotid-Artery Stenting Beneficial for Carotid Stenosis

Adding carotid-artery stenting—but not carotid endarterectomy—to intensive medical management reduced the risk of stroke or death in patients with high-grade asymptomatic carotid stenosis. In two parallel, observer-blinded trials including more than 2,400 participants with ≥70% stenosis, the 4-year incidence of the primary composite outcome (any stroke or death from randomization […]


Mental Wellbeing Mitigated IBS Risk

Better mental wellbeing substantially reduces the risk of developing irritable bowel syndrome (IBS), with effects that are independent of genetic predisposition and partly mediated through lower depression and anxiety. In this prospective UK Biobank cohort of 75,842 IBS-free participants followed for 12.4 years, 1,400 incident IBS cases occurred, and higher […]


Secondary CVD Prevention with Colchicine

Low-dose colchicine reduces myocardial infarction and stroke in people with cardiovascular disease (CVD) without increasing serious adverse events, although it raises the risk of mild gastrointestinal symptoms and shows no clear effect on mortality or revascularization. In an updated Cochrane review of 12 randomized controlled trials including 22,983 participants followed […]


Early Zalunfiban Injection Effective for Major Heart Attack:

In patients with ST-segment elevation myocardial infarction (STEMI), early subcutaneous administration of zalunfiban significantly improved coronary artery patency and reduced the risk of adverse 30-day clinical outcomes without increasing severe bleeding. In an international, double-blind, placebo-controlled trial of 2,467 patients randomly assigned to receive zalunfiban (0.11 mg/kg or 0.13 mg/kg) […]